Overview

Agaricus blazei Murill (ABM), also known as Agaricus subrufescens or "Cogumelo do Sol" (Mushroom of the Sun), is an edible basidiomycete mushroom originally identified in the Piedade region of São Paulo, Brazil. It has a long history of use in traditional Brazilian and Japanese medicine. The mushroom is particularly rich in β-glucans—polysaccharides with β-(1→3) and β-(1→6) linkages—which are believed to be the primary bioactive compounds responsible for its immunostimulatory effects.

Research on Agaricus blazei has focused primarily on its immunomodulatory and potential antitumor activities. In vitro and animal studies have demonstrated that ABM extracts can activate macrophages, natural killer cells, and dendritic cells, enhancing both innate and adaptive immune responses. Several clinical studies, particularly from Japan, have investigated ABM as an adjunctive therapy during chemotherapy, reporting improvements in natural killer cell activity and quality of life in cancer patients, though results are mixed and larger confirmatory trials are needed.

Beyond immunology, Agaricus blazei has been studied for antioxidant, hepatoprotective, anti-diabetic, and anti-allergic properties. The mushroom contains a variety of bioactive compounds including ergosterol, agaritine, pyroglutamate, and various phenolic compounds. It is commercially available as a dietary supplement in powder, capsule, and extract forms. While generally considered safe, there have been rare case reports of hepatotoxicity associated with ABM extract consumption, and individuals with autoimmune conditions should consult a healthcare provider before use.

Mechanism of Action

Beta-Glucan Immunomodulation

Agaricus blazei Murill (ABM) contains high concentrations of immunoactive β-glucans, primarily β-(1,3)-D-glucan with β-(1,6)-D-glucan side branches. These polysaccharides bind to pattern recognition receptors on innate immune cells: Dectin-1, complement receptor 3 (CR3/CD11b/CD18), and Toll-like receptor 2 (TLR2), triggering immune activation cascades (PMID: 15811808).

Innate Immune Cell Activation

Dectin-1 engagement activates Syk kinase → CARD9/BCL10/MALT1 signalosome → NF-κB and NFAT transcription factors, driving production of TNF-α, IL-1β, IL-6, and IL-12. Macrophages are polarized toward an M1 phenotype with enhanced phagocytosis and respiratory burst activity. NK cell cytotoxicity is increased through upregulation of perforin and granzyme B expression.

Adaptive Immune Enhancement

IL-12 produced by activated macrophages and dendritic cells promotes Th1 polarization of CD4+ T cells, increasing IFN-γ production. This enhances cytotoxic CD8+ T cell responses. ABM polysaccharides also act as adjuvants, improving antigen presentation through upregulation of MHC class II and co-stimulatory molecules (CD80, CD86) on dendritic cells (PMID: 18955364).

Anti-tumor Mechanisms

ABM extracts demonstrate anti-tumor activity through complement activation via the alternative pathway, increased NK and LAK cell activity, and induction of tumor cell apoptosis. The proteoglucan fraction inhibits tumor angiogenesis by reducing VEGF expression.

Antioxidant Components

Phenolic compounds, ergosterol derivatives, and agaritine metabolites in ABM provide additional antioxidant capacity, scavenging reactive oxygen species and chelating transition metals to reduce oxidative damage.

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Gastrointestinal symptoms including nausea, diarrhea, abdominal discomfort, and stomach upset are the most commonly reported adverse effects, occurring in roughly 5-15% of users.
• Allergic reactions ranging from mild skin rash to more severe hypersensitivity responses in mushroom-sensitive individuals.
• Mild dizziness and headache have been reported in some clinical studies.
• Dry mouth and throat irritation with powdered formulations.

Contraindications

• Known allergy to Agaricus species or other Basidiomycete mushrooms. Cross-reactivity with other mushroom allergens is possible.
• Active autoimmune conditions: As a potent immunostimulant, Agaricus blazei may exacerbate autoimmune diseases including lupus, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
• Severe hepatic impairment: Case reports from Japan have documented hepatotoxicity associated with Agaricus blazei supplementation, including elevated transaminases and cholestatic liver injury requiring hospitalization.
• Patients undergoing organ transplantation or on immunosuppressive therapy.

Drug Interactions

• Immunosuppressants (cyclosporine, tacrolimus, sirolimus, corticosteroids): Agaricus blazei polysaccharides (particularly beta-glucans and proteoglycans) may antagonize immunosuppressive effects through macrophage and NK cell activation.
• Antidiabetic medications: Agaricus blazei has demonstrated hypoglycemic properties in clinical trials; concurrent use with insulin or oral hypoglycemics may cause additive blood sugar lowering.
• Anticoagulants and antiplatelet agents: Some Agaricus extracts have shown antiplatelet aggregation activity, potentially increasing bleeding risk when combined with warfarin, aspirin, or clopidogrel.
• Chemotherapeutic agents: While some preclinical data suggest synergistic anticancer effects, unpredictable interactions with cytotoxic drugs warrant physician oversight.

Special Populations

• Pregnancy and lactation: No adequate safety data; use is not recommended.
• Pediatric use: Limited clinical evidence in children; caution advised.
• Hepatically impaired patients: Contraindicated due to documented hepatotoxicity cases; if used, requires close hepatic monitoring.

Monitoring

• Liver function tests (ALT, AST, ALP, GGT, bilirubin) at baseline and every 4-8 weeks during supplementation, given documented hepatotoxicity risk.
• Blood glucose levels in diabetic patients.
• Complete blood count and immune markers in immunocompromised individuals.
• Signs of allergic reaction, especially during the first 2 weeks of use.

Pharmacokinetic Profile